C4 Therapeutics, Inc. Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2026-08-11: Form 10-Q; Exhibit 10.2; Description Research Collaboration and License Agreement, between the Registrant and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated April 8, 2026.
- 2026-06-24: Form 8-K; Exhibit 10.1; Description Amendment No. 2 to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan.
- 2026-02-26: Form 10-K; Exhibit 10.18; Description Form of Performance-Accelerated Restricted Stock Unit Award Agreement.
- 2025-02-27: Form 10-K; Exhibit 10.19; Description Research Collaboration and License Agreement dated March 1, 2024, by and between C4 Therapeutics, Inc., and Merck KGaA, Darmstadt, Germany.
| Filed | Form | Exhibit | Description |
|---|
| 2026-08-11 | 10-Q | 10.2 | Research Collaboration and License Agreement, between the Registrant and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated April 8, 2026 |
|---|
| 2026-06-24 | 8-K | 10.1 | Amendment No. 2 to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan |
|---|
| 2026-02-26 | 10-K | 10.18 | Form of Performance-Accelerated Restricted Stock Unit Award Agreement |
|---|
| 2025-02-27 | 10-K | 10.19 | Research Collaboration and License Agreement dated March 1, 2024, by and between C4 Therapeutics, Inc., and Merck KGaA, Darmstadt, Germany |
|---|
| 2024-10-16 | 8-K/A | 10.1 | Consulting Agreement dated as of October 15, 2024, between C4 Therapeutics, Inc. and Stewart Fisher |
|---|
| 2024-10-15 | 8-K | 10.1 | Consulting Agreement dated as of October 15, 2024, between C4 Therapeutics, Inc. and Stewart Fisher |
|---|
| 2024-10-11 | 8-K | 10.1 | Amendment No. 1 to C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan |
|---|
| 2024-05-08 | 10-Q | 10.1 | Research Collaboration and License Agreement dated March 1, 2024, by and among C4 Therapeutics, Inc., and Merck KGaA, Darmstadt, Germany |
|---|
| 2024-02-22 | 10-K | 10.19 | Form of Non-Qualified Stock Option Agreement Inducement Award |
|---|
| 2024-02-22 | 10-K | 10.18 | License and Collaboration Agreement, dated December 11, 2023, by and between C4 Therapeutics, Inc. and Merck Sharp & Dohme LLC |
|---|
| 2023-05-30 | 8-K | 10.2 | Stock Purchase Agreement, dated May 29, 2023, by and among C4 Therapeutics, Inc., Betta Pharmaceuticals Co., Ltd. and Betta Investment (Hong Kong) Limited. |
|---|
| 2023-05-30 | 8-K | 10.1 | License and Collaboration Agreement, dated May 29, 2023, by and between C4 Therapeutics, Inc. and Betta Pharmaceuticals Co., Ltd. |
|---|
| 2023-02-23 | 10-K | 10.2 | 2020 Stock Option and Incentive Plan and forms of award agreements thereunder |
|---|
| 2021-11-30 | 8-K | 10.1 | Lease Amendment, dated November 24, 2021, by and between C4 Therapeutics, Inc. and Columbia Massachusetts Arsenal Office Properties, LLC |
|---|
| 2021-03-11 | 10-K | 10.13 | First Amendment to the Amended and Restated License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated November 12, 2020 |
|---|
| 2021-03-11 | 10-K | 10.11 | Amendment No. 1 to Collaborative Research and License Agreement between the Registrant and Biogen MA, Inc., dated February 25, 2020 |
|---|